SMS Pharmaceuticals Share Price Rise Nearly 16% After US FDA Approval For Reformulated Ranitidine

Hyderabad, November 26, 2025: SMS Pharmaceuticals Ltd saw a sharp rise in its stock price on Wednesday after the firm revealed through a filing with the Securities Exchange Board of India that its subsidiary VKT Pharma had gained approval from the United States FDA for the sale of reformulated Ranitidine tablets. As of 12:50 IST Wednesday, SMS Pharmaceuticals’ stock was trading at ₹316.40 per share, representing a ₹42.85 increase or 15.66% compared to yesterday’s close of ₹274.00. The share began trading at ₹277.70 and has traded between a low of ₹276.50 and a high of ₹320.50. The company has a current market capitalisation of ₹2,425.10 crores and a price earnings (P/E) ratio of 28.70.

What Triggered The Rally

As stated in the press release submitted to the stock markets, VKT Pharma has received approval from the US Food and Drug Administration for its new version of Ranitidine 150mg and 300mg tablets. This marks VKT Pharma’s return to the United States after almost five years.

The notice of filing indicates that the manufacturer received FDA approval after extensive testing of its product’s safety and improvements in the manufacturing process, specifically addressing issues concerning the formation of NDMA impurities. The manufacturer believes the approval will enhance patient access to the acid-reducing therapy, which is widely used.

Company Announcement

On 26th November, SMS Pharmaceuticals published an announcement stating that approval of their newer form of ranitidine has been granted. An increase in the product’s safety standards was made to benefit those individuals using this product for numerous conditions.

SMS Pharmaceuticals Ltd. is a small-cap publicly traded Pharmaceutical Manufacturer engaged in manufacturing Active Pharmaceutical Ingredients and formulations. SMS Pharmaceuticals Ltd. trades on the BSE and NSE and is included within the BSE SmallCap index with the core industry classification of Pharmaceuticals.

REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/87262c23-398d-436b-974b-df77efe62e48.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations